Halozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call Transcript
HALO earnings call for the period ending September 30, 2019.
Halozyme Therapeutics
HALO
HALO
$19.16
$0.10
0.5%
BATS BZX Real Time Price as of December 6, 2019, 4:00 p.m. EST
View Interactive HALO Charts
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
News & Analysis: Halozyme Therapeutics
The Fool has written over 100 articles on Halozyme Therapeutics.
Halozyme Therapeutics Inc (HALO) Q2 2019 Earnings Call Transcript
HALO earnings call for the period ending June 30, 2019.
Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript
HALO earnings call for the period ending March 31, 2019.
3 Cancer Treatment Stocks to Buy in March
Find out why these oncology-focused companies stand out as great opportunities right now.
Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
HALO earnings call for the period ending December 31, 2018.
This News Explains Halozyme Therapeutics' Double-Digit Drop Today
Shares fall after an analyst lowers his price target. Here's what investors need to know.
3 Top Stocks Wall Street Is Overlooking
Just because investors are ignoring these three gems doesn't mean that you have to.
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
Investors cheer better-than-expected earnings and a guidance boost. Could there be more upside ahead?
3 Monster Stocks in the Making
Halozyme Therapeutics, FMC Corp., and Braskem all have major opportunities in front of them that could lead to outsize returns.
1 Great Biotech Stock You Have Never Heard Of
Big pharma companies have thrown hundreds of millions of dollars at this small biotech. Should retail investors follow suit?
